CD40 in CIN and cervical cancer: An immunohistochemical analysis revealing an intriguing expression profile

2000 ◽  
Vol 70 ◽  
pp. D86-D86
Author(s):  
G.R. Teale ◽  
Y.-L. Hock ◽  
D.M. Luesley ◽  
L.S. Young
Keyword(s):  
Cervical Cancer ◽  
Expression Profile ◽  
Immunohistochemical Analysis

scholarly journals The effect of HMGB1 on the clinicopathological and prognostic features of cervical cancer

2019 ◽  
Vol 39 (5) ◽  
Author(s):  
Pan Li ◽  
Mengfei Xu ◽  
Hongbing Cai ◽  
Niresh Thapa ◽  
Can He ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Molecular Mechanisms ◽  
Bioinformatics Analysis ◽  
Immunohistochemical Analysis ◽  
Figo Stage ◽  
P Value ◽  
Prognostic Features ◽  
Potential Biomarker ◽  
Hmgb1 Expression

Abstract Cervical cancer is the third leading cause of cancer death among women in less-developed regions. Because of the poor survivorship of patients with advanced disease, finding new biomarkers for prognostic prediction is of great importance. In the current study, mRNA datasets (GSE9750 and GSE63514) were retrieved from Gene Expression Omnibus and was used to identify differentially expressed genes. The underlying molecular mechanisms associated with high-mobility group box 1 protein (HMGB1) were investigated using bioinformatics analysis. Immunohistochemical analysis of HMGB1 was performed on 239 cases of cervical cancer samples to investigate its possible correlation with clinicopathological characteristics and outcomes. A preliminary validation has been made to explore the possible correlation factors with HMGB1 that promote migration of cervical cancer cells. Bioinformatics analysis showed that adherens junction was significant for both P-value and enrichment scores, which was consistent with the clinical study. The underlying molecular mechanisms might be the interaction among HMGB1, RAC1, and CDC42. HMGB1 expression was significantly associated with tumor size, parametrial infiltration, the depth of cervical stromal invasion, and FIGO stage (P=0.003, 0.019, 0.013, and 0.003, respectively). FIGO stage, lymph mode metastasis, and HMGB1 expression were independent predictors of a poorer prognosis of patients with cervical cancer. Knockdown of HMGB1 inhibits migration of Siha and C33A cells in vitro. Western blot and quantitative real-time PCR (qRT-PCR) showed that the expression of RAC1 and CDC42 was positively correlated with HMGB1. HMGB1 is a useful prognostic indicator and a potential biomarker of cervical cancer. RAC1 and CDC42 may be involved in the progression of cervical cancer migration induced by HMGB1.

scholarly journals Expression profile of circulating microRNAs as a promising fingerprint for cervical cancer diagnosis and monitoring

2015 ◽  
Vol 3 (4) ◽  
pp. 851-858 ◽  
Author(s):  
WENHUI JIA ◽  
YUANZHE WU ◽  
QIN ZHANG ◽  
GE GAO ◽  
CHENYU ZHANG ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Expression Profile ◽  
Cancer Diagnosis ◽  
Circulating Micrornas

scholarly journals Unique Gene Expression Profile Associated with an Early-Onset Multiple Endocrine Neoplasia (MEN1)-Associated Pituitary Adenoma

2011 ◽  
Vol 96 (11) ◽  
pp. E1905-E1914 ◽  
Author(s):  
William E. Farrell ◽  
Monalisa F. Azevedo ◽  
Dalia L. Batista ◽  
Alastair Smith ◽  
Isabelle Bourdeau ◽  
...  
Keyword(s):  
Pituitary Adenoma ◽  
Expression Profile ◽  
Early Onset ◽  
Pituitary Tumor ◽  
Multiple Endocrine Neoplasia ◽  
Expression Profiles ◽  
Immunohistochemical Analysis ◽  
Tumor Formation ◽  
Tumor Evolution ◽  
Endocrine Neoplasia

Abstract Context: Multiple endocrine neoplasia type 1 (MEN1) is caused by mutations in the menin (MEN1) gene. The mechanism(s) by which MEN1 mutations lead to pituitary tumor formation remain(s) unknown. Objective: The aim of the study was to identify the pediatric MEN1-associated pituitary tumor transcriptome. Patients and Methods: A patient harboring a MEN1 mutation (c.525C>G; p.H139D) who presented with an early-onset mammosomatotroph pituitary adenoma was studied. Microarray analysis was performed in the tumor sample and compared with the profile observed in normal pituitaries and in a sporadic mammosomatotropinoma. Validation of the microarray results was performed using quantitative real-time PCR and immunohistochemical analysis for selected genes. Results: In the MEN1-associated pituitary adenoma, 59 and 24 genes were found to be significantly up- and down-regulated, respectively. The up-regulated genes included those involved in cell growth and maintenance, apoptosis, growth arrest, and tumorigenesis. Moreover, we observed decreased expression in genes neuroendocrine in nature and related to growth or apoptosis. Only 21 of the 59 genes differentially expressed in the MEN1-associated adenoma showed a similar expression profile to that seen in the sporadic mammosomatotropinoma; for some genes an opposite expression profile was observed. Conclusions: We identified changes in the transcriptome that occur in pituitary GH- and PRL-producing cells after the loss of menin expression; some of the gene changes are necessary for tumor evolution, and others may be tertiary. Nevertheless, the rare overlap between the expression profiles of the MEN1 tumor vs. that of its sporadic counterpart suggests that these tumors evolve along different molecular pathways.

scholarly journals Carcinosarcoma of the Cervix: A Case Report

2021 ◽  
Vol 59 (240) ◽  
Author(s):  
Birendra Bhagat ◽  
Bijaya Chandra Aacharya ◽  
Sarita Gurung ◽  
Ranjan Raj Bhatta ◽  
Aasiya Rajbhandari
Keyword(s):  
Cervical Cancer ◽  
Cervical Carcinoma ◽  
Case Reports ◽  
Immunohistochemical Analysis ◽  
Abdominal Hysterectomy ◽  
Primary Treatment ◽  
Resected Specimen ◽  
Sarcomatous Component ◽  
Common Cause ◽  
Cervical Biopsy

Cervical carcinoma is the most common cause of mortality due to cancer in Nepal. Carcinosarcoma is a very rare subtype of cervical cancer which is characterized by the presence of both epithelial and mesenchymal malignant component. It constitutes less than 1% of cervical carcinoma. Due to the low occurrence of the disease, most of the data on treatment and prognosis are based on case reports and series. Here, we report a case of 69 years, female with cervical cancer (FIGO IIA2). Histopathological and immunohistochemical analysis of cervical biopsy initially showed primary adenosarcoma of the cervix. The tumor was non-responsive to primary treatment with concurrent chemoradiation. Later she was treated with abdominal hysterectomy and bilateral salpingo-oophorectomy. The final histopathology of the resected specimen showed a sarcomatous component along with carcinomatous changes in the endocervical glands favouring the diagnosis of carcinosarcoma of the cervix.

Increased Cyclooxygenase-2 Expression Is Associated With Chemotherapy Resistance and Poor Survival in Cervical Cancer Patients

2002 ◽  
Vol 20 (4) ◽  
pp. 973-981 ◽  
Author(s):  
G. Ferrandina ◽  
L. Lauriola ◽  
M. G. Distefano ◽  
G. F. Zannoni ◽  
M. Gessi ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Patients ◽  
Early Stage ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Rabbit Antiserum ◽  
Immunohistochemical Analysis ◽  
Response To Treatment ◽  
Advanced Stage ◽  
Cox 2

PURPOSE: To investigate the expression of cyclooxygenase (COX-2) and its association with clinicopathologic parameters and clinical outcome in patients with cervical cancer. PATIENTS AND METHODS: The study included 84 patients with stage IB to IVA cervical cancer. Patients with early-stage cases (n = 21) underwent radical surgery, whereas patients with locally advanced cervical cancer (LACC) (n = 63) were first administered neoadjuvant cisplatin-based treatment and subjected to surgery in case of response. Immunohistochemical analysis was performed on paraffin-embedded sections with rabbit antiserum against COX-2. RESULTS: COX-2–integrated density values in the overall population ranged from 1.2 to 82.3, with mean ± SE values of 27.4 ± 2.4. According to the chosen cutoff value, 36 (42.9%) of 84 patients were scored as COX-2 positive. COX-2 levels were shown to be highly associated with tumor susceptibility to neoadjuvant treatment. COX-2 showed a progressive increase from mean ± SE values of 19.9 ± 8.0 in complete responders through 31.5 ± 3.5 in partial responses to 44.8 ± 3.9 in patients who were not responsive (P = .0054). When logistic regression was applied, only advanced stage and COX-2 positivity retained independent roles in predicting a poor chance of response to treatment. COX-2–positive patients had a shorter overall survival (OS) rate than COX-2–negative patients. In patients with LACC, the 2-year OS rate was 38% in COX-2–positive versus 85% in COX-2–negative patients (P = .0001). In the multivariate analysis, only advanced stage and COX-2 positivity retained independent negative prognostic roles for OS. CONCLUSION: The assessment of COX-2 status could provide additional information to identify patients with cervical cancer with a poor chance of response to neoadjuvant treatment and unfavorable prognosis.

Immunohistochemical analysis of pelvic lymph node micrometastases in cervical cancer patients with histologically negative nodes

2006 ◽  
Vol 17 (3) ◽  
pp. 200
Author(s):  
Jeong Sig Kim ◽  
Kye Hyun Nam ◽  
Hae Hyeog Lee ◽  
Hee Kyung Kim ◽  
Dong Han Bae
Keyword(s):  
Cervical Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Immunohistochemical Analysis ◽  
Pelvic Lymph Node ◽  
Lymph Node Micrometastases

P16INK4A Immunohistochemistry as a Gold Standard for Cervical Cancer and Precursor Lesions Screening

2020 ◽  
Author(s):  
Mahdieh FARZANEHPOUR ◽  
Ahad MUHAMMADNEJAD ◽  
Setareh AKHAVAN ◽  
Mir Nader EMAMI RAZAVI ◽  
Somayeh JALILVAND ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Invasive Cervical Cancer ◽  
Immunohistochemical Analysis ◽  
Human Papillomaviruses ◽  
Low Grade ◽  
Operating Characteristics ◽  
Hpv Dna ◽  
Diagnosis And Prognosis ◽  
Tissue Specimens ◽  
Intraepithelial Lesions

Background: High-risk (HR) Human papillomaviruses (HPVs) are known as the main factors implicated in the pathogenesis of cervical preinvasive and invasive lesions. Therefore, the presence or absence of HR-HPV can be followed for the prognosis of low-grade and high-grade squamous intraepithelial lesions. Since the overexpression of p16INK4a protein depends on the presence of transcriptionally-active HPV, and due to its availability and simple interpretation, it may be considered as a proper marker to diagnose cervical cancer. Methods: An immunohistochemical analysis of p16INK4a was performed in 72 cervical tissue specimens at Imam Khomeini Complex Hospital (Tehran, Iran) from 2016 to 2018. The performance parameters were calculated and compared using receiving operating characteristics curve (ROC) details. Results: p16INK4a is significantly up-regulated in the cervical cancer samples in comparison with that in normal samples. Moreover, the ROC data showed the potential ability of p16INK4a under determined conditions as a diagnostic marker for CIN 2-3 staging and invasive cervical cancer. The molecular typing disclosed the attendance of HPV DNA in 44.4% of cases (32/72) with a predominance of HPV type 16. Conclusion: The molecular biomarker p16INK4a can be a good candidate for the early diagnosis and prognosis of cervical cancer in HPV-infected patients. Considering the increase in the expression level of p16INK4a in cancer and precancer tissues, p16INK4a may be used for early detection of cervical cancer.

scholarly journals Long non-coding RNA expression profile in cervical cancer tissues

2017 ◽  
Vol 14 (2) ◽  
pp. 1379-1386 ◽  
Author(s):  
Hua Zhu ◽  
Xiangjian Chen ◽  
Yan Hu ◽  
Zhengzheng Shi ◽  
Qing Zhou ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Expression Profile ◽  
Rna Expression ◽  
Non Coding Rna ◽  
Cancer Tissues ◽  
Long Non Coding Rna

Computer-assisted Immunohistochemical Analysis of Cervical Cancer Biomarkers Using Low-cost and Simple Software

2007 ◽  
Vol 15 (4) ◽  
pp. 456-462 ◽  
Author(s):  
Luciano Serpa Hammes ◽  
Jeffrey E. Korte ◽  
Rajeshwar Rao Tekmal ◽  
Paulo Naud ◽  
Maria Isabel Edelweiss ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Low Cost ◽  
Immunohistochemical Analysis ◽  
Cancer Biomarkers ◽  
Computer Assisted

scholarly journals Evaluation of Serum Levels and Expression of Galectin-4 in Cervical Cancer

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Ileana Conde-Rodríguez ◽  
Guadalupe Delgado-López ◽  
Erick Armenta-Castro ◽  
Ivonne Ramírez-Díaz ◽  
Maricruz Anaya-Ruiz ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Tumor Cells ◽  
Clinical Stage ◽  
Immunohistochemical Analysis ◽  
Serum Levels ◽  
Early Recurrence ◽  
Cervical Tissue ◽  
Normal Cytology ◽  
Advanced Clinical Stage ◽  
Cancer Types

Galectin-4 has been reported to be altered in different cancer types. Its expression changes have been associated with early recurrence and metastasis. In cervical cancer (CC), galectin-4 has not been studied. The aim of the study was to determine the expression level and subcellular localization of galectin-4 in CC tissue and the concentration in the serum of patients with CC. For the analysis of serum levels of galectin-4, an ELISA assay was performed. To assess the expression in cervical tissue, immunohistochemical staining was performed. The results showed that the concentration of galectin-4 in the serum of patients with CC was higher (647.9 pg/ml) than that in the serum of women with normal cytology (382.1 pg/ml). The immunohistochemical analysis of CC samples showed a higher expression in keratinizing tumor than nonkeratinizing tumors and a trend of increased expression in tumors from patients with advanced clinical stage. In normal cervical tissue, galectin-4 was detected in the cytoplasm, and in tumor cells, the presence of galectin-4 was also detected in the nucleus, in both adenocarcinoma and squamous cervical cancer. The increase in serum concentration and different localization in the tumor cells suggest a possible role of galectin-4 in CC development.

Sign in / Sign up

Export Citation Format

Share Document